Aligos Therapeutics, Inc. - ALGS STOCK NEWS

Aligos Therapeutics (Nasdaq: ALGS) announced that eight abstracts have been accepted for presentation at the European Association for the Study of the Liver (EASL) Congress 2025, scheduled for May 7-10, 2025 in Amsterdam. The presentations focus on two key drug candidates:

1. ALG-000184: A potential first/best-in-class small molecule CAM-E for chronic hepatitis B virus infection, with three abstracts highlighting its profound HBV DNA suppression in 96-week studies and resistance barrier analysis.

2. ALG-055009: A potential best-in-class thyroid hormone receptor beta agonist for Metabolic Dysfunction-Associated Steatohepatitis (MASH), with four abstracts demonstrating significant reductions in atherogenic lipids and liver fat, including studies in combination with GLP-1 receptor agonists.

Aligos Therapeutics (ALGS) announced positive data from three presentations at APASL 2025, highlighting significant progress in their liver disease treatments. ALG-000184 demonstrated strong antiviral activity in chronic hepatitis B patients, with 100% of HBeAg+ subjects (9/9) and 91% of HBeAg- subjects achieving sustained HBV DNA suppression, with no viral resistance observed up to 96 weeks.

The company's ALG-055009 showed promising results in MASH patients, with doses of 0.5-0.9mg achieving placebo-adjusted median relative reductions in liver fat up to 46.2%. Up to 70% of subjects achieved ≥30% reduction in liver fat. Notably, 11/14 subjects on stable GLP-1 agonists treated with ALG-055009 showed liver fat decreases, while all 4 placebo subjects on GLP-1 agonists experienced increases.

Aligos Therapeutics (Nasdaq: ALGS), a clinical stage biopharmaceutical company specializing in liver and viral diseases, has announced an inducement grant under Nasdaq Listing Rule 5635(c)(4). The company's Compensation Committee approved a non-qualified stock option to purchase 4,000 shares for a newly hired employee on March 11, 2025.

The grant, issued through Aligos' 2024 Inducement Plan, serves as an employment inducement and has an exercise price matching the closing price of Aligos' common stock on the grant date. The shares will vest over four years, with 25% vesting after the first year and the remaining portion vesting in equal monthly installments, contingent on continued employment.

Aligos Therapeutics (ALGS) reported its Q4 and full year 2024 financial results, highlighting significant progress in its pipeline. The company completed a $105 million private placement in February 2025. Their lead candidate ALG-000184, a CAM-E therapy for chronic hepatitis B virus infection, showed promising Phase 1 results with 100% HBV DNA suppression in tested subjects.

Financial results showed a net loss of $82.2 million for Q4 2024 ($13.08 per share), compared to $27.9 million loss in Q4 2023. Full-year 2024 net loss was $131.2 million. Cash position stood at $56.9 million as of December 31, 2024. The recent financing is expected to fund operations into second half of 2026.

R&D expenses decreased to $16.0 million in Q4 2024 from $22.3 million in Q4 2023. G&A expenses reduced to $5.2 million from $6.4 million in the same period. The company plans to begin Phase 2 studies for ALG-000184 in mid-2025.

Aligos Therapeutics (Nasdaq: ALGS), a clinical stage biotech company specializing in liver and viral disease therapies, has scheduled its fourth quarter 2024 financial results announcement for Monday, March 10, 2025. The results will be released before U.S. financial markets open.

Aligos Therapeutics (NASDAQ: ALGS) has secured a $105 million private placement financing, led by a life sciences dedicated investment firm with participation from new and existing institutional investors. The company is selling 2,103,307 shares of common stock (1,427,000 voting and 676,307 non-voting), pre-funded warrants for up to 1,922,511 voting shares, and warrants for up to 2,012,909 voting shares.

The combined price is $26.0825 per share of common stock and accompanying warrant, with pre-funded warrants priced at $26.0824. The warrants will have an exercise price of $26.02 per share and will expire on February 13, 2032. The proceeds will fund the ALG-000184 Phase 2 clinical study in chronic hepatitis B virus infection and extend the company's cash runway into the second half of 2026.

Aligos Therapeutics (ALGS) has announced an inducement grant of non-qualified stock options to a newly hired employee. The grant, issued on December 10, 2024, allows for the purchase of 5,500 shares of company stock. The exercise price equals the closing price of Aligos' common stock on the grant date. The shares will vest over four years, with 25% vesting after the first year and the remainder vesting in equal monthly installments, contingent on continued employment. The grant was made under Aligos' 2024 Inducement Plan, exclusively used for equity awards to new hires, in compliance with Nasdaq Listing Rule 5635(c)(4).

Aligos Therapeutics (Nasdaq: ALGS), a clinical stage biopharmaceutical company specializing in liver and viral diseases, has announced its participation in two major investor conferences this December. The company will present at the Piper Sandler 36th Annual Healthcare Conference at 11:00am ET and the Evercore ISI 7th Annual HealthCONx Conference at 4:15pm ET, both on December 3, 2024.

Management will conduct fireside chats at both events and participate in one-on-one meetings. The presentations will be webcast live on the company's investor relations website, with replays available for at least 30 days afterward.

Aligos Therapeutics (ALGS) presented positive data at The Liver Meeting 2024, highlighting two key developments: First, ALG-000184 showed sustained antiviral activity in chronic hepatitis B patients, with 100% of HBeAg-positive subjects achieving HBV DNA suppression at 84 weeks, and 91% of HBeAg-negative subjects reaching below detection limits at 48 weeks. Second, their THR-β agonist ALG-055009 demonstrated significant liver fat reduction in MASH patients, with up to 46.2% placebo-adjusted median reductions at 12 weeks. Notably, 70% of subjects achieved ≥30% liver fat reduction, and the drug showed effectiveness in patients on GLP-1 agonists. Both compounds were well-tolerated with no significant safety concerns.